Health Condition 1: J849- Interstitial pulmonary disease, unspecified
Conditions
Interventions
Intervention1: Tab Gabapentin 300 mg TDS or max tolerable dose for 8 weeks: 300 mg TDS or max tolerable dose for 8 weeks
Control Intervention1: Syp Levocloperstine: 10 ml TDS
Sponsors
None
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged 18 years to 70 years of age. Individuals classified with interstitial lung disease according to the most recent diagnostic criteria established by the American Thoracic Society. Patients with chronic intractable cough, that is cough more than eight weeks with a severity of more than 40mm on VAS score. Patients with no contraindications to Gabapentin treatment
Exclusion criteria
Exclusion criteria: Patients who give negative informed consent. Patients with exposure to Gabapentin or Pregabalin within 2 months. Upper respiratory tract infection within 2 months. Current or ex-smokers. Patients presenting with acute exacerbation of ILD. Patients with co-morbidities like Obstructive airway disease, Gastroesophageal reflux disease or Congestive Cardiac Failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean LCQ scores in study group and control groupTimepoint: Baseline, 4, 8 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Cough severity score (VAS SCORE) in study group and control group 2. Modified Borg‘s Dyspnea score in the study group and control group 3. Occurrence of adverse events (AE) / Severe adverse events (SAE) 4. After discontinuation of Gabapentin, change in LCQ and VAS score after 4 weeks.Timepoint: Baseline, 4, 8 and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Aneri Parekh
All India Institute of Medical Sciences, Bhubaneswar
Outcome results
None listed